Hybridoma technology is a technology of forming hybrid cell lines (hybridomas) by fusing a specific antibody-producing B cell with a myeloma (B cell cancer) cell that is selected for its ability to grow in tissue culture and for an absence of antibody chain synthesis. The antibodies produced by the hybridoma are all of a single specificity and are therefore monoclonal antibodies.
Creative Biolabs provides a full range of services in custom polyclonal and monoclonal antibody production from gene expression or peptide synthesis to antibody purification and labeling. We can produce antibodies in either research quantities or on a large scale for the diagnostic industry. We do epitope prediction, peptide synthesis, protein expression, polyclonal or monoclonal antibody production as well as antibody purification from cell culture, ascites fluid, or whole serum.
Hybridoma technology produces monoclonal antibodies against antigens. The monoclonal antibodies prepared by this method are highly specific and derived from the monoclonal antibodies of the parental B cells.
Fig.1 Flow chart of hybridoma technology.
At least 2 rounds of specific ELISA screening and 2 rounds hybridoma subclone.
Sequencing (covering variable regions: VH and VL) and report (both DNA and amino acid sequences, with CDR regions highlighted).
90-120 days. The time may vary depending on the different requirment, and additional time should be allowed for additional validation testing or repetition, if necessary.
As a highly optimized service, our liposome immunization technology relies on a proprietary liposome immunization procedure using liposome-encapsulated antigens, which including but not limited to the polysaccharide, lipid, glycolipid, and DNA.
Our proprietary mouse immunization approach allows us to provide mouse monoclonal antibodies within 70 days.
We have developed a proprietary hybridoma-generation platform for efficient development of high-affinity and high-specificity rat monoclonal antibodies.
We have extensive experience in producing monoclonal antibodies in hamsters.
Through fusing with our specific myeloma as partner, guinea pig hybridoma can be developed with excellent stability and productivity.
The immunization of "knock-out" mice was an effective way to overcome the problem of inter-species sequence similarity in antibody production.
We provide custom anti-small molecule mAb development services through hybridoma technology.
It is important to determine the application and hybridoma screening method since not all antibodies will work with every application.
We now have the capability and technology platforms to offer you diverse hybridoma rescue services.
Immunogen design service is one of our core technical services. We offer complementary protein expression or peptide design services to generate custom antibodies with better performance.
Delivering the final products with fast turnaround time and high quality.
We provide world-class packaging services for hybridoma isotype Identification and switching.
As an industrial leader specializing in custom services, Creative Biolabs also provides gene-engineered antibodies including single domain antibodies and humanized antibodies. Moreover, we can conduct phage display antibody library screening and antibody development by single B cell sorting platform. Contact us for more information.
The client provided a protein target X, we designed a peptide immunogen and did the function test of selected positive hybridoma. Fig.2 is the ELISA titration result in the immunization process. Fig.3 is the ELISA result of the finally selected hybridomas.
The client provided the sequence of the target protein. Creative Biolabs was contracted to develop monoclonal antibodies targeting different epitopes on protein through mouse immunization and hybridoma screening.
Use the resources in our library to help you understand your options and make critical decisions for your study.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.